Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Teratogen update: ergot and ergotamine

G V Raymond1

  • 1Kennedy Krieger Institute, Baltimore, Maryland 21205, USA.

Teratology
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Ergotamine, a medication for migraines, may pose risks during pregnancy. While animal studies show harm at toxic doses, human data is limited, suggesting caution and avoidance in pregnant individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo loss of function mutations in KIAA2022 are associated with epilepsy and neurodevelopmental delay in females.

Clinical genetics·2016
Same author

Childhood Cerebral Adrenoleukodystrophy: MR Perfusion Measurements and Their Use in Predicting Clinical Outcome after Hematopoietic Stem Cell Transplantation.

AJNR. American journal of neuroradiology·2016
Same author

Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients.

AJNR. American journal of neuroradiology·2015
Same author

Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines.

Molecular genetics and metabolism·2015
Same author

Onset of adreno-leukodystrophy after medulloblastoma therapy: causal connection or coincidence?

JIMD reports·2013
Same author

Contrast enhancement of brainstem tracts in Zellweger spectrum disorder: evidence of inflammatory demyelination?

Neuropediatrics·2011
Same journal

Statement of the Public Affairs Committee of the Teratology Society on the fetal alcohol syndrome.

Teratology·2002
Same journal

Quantification and localization of expression of the retinoic acid receptor-beta and -gamma mRNA isoforms during neurulation in mouse embryos with or without spina bifida.

Teratology·2002
Same journal

Timing of prenatal care initiation and risk of congenital malformations.

Teratology·2002
Same journal

A new rapid radiological procedure for routine teratological use in bone ossification assessment: a supplement for staining methods.

Teratology·2002
Same journal

Dose and litter allocations in the design of teratological studies for detecting hormesis.

Teratology·2002
Same journal

Effect of sera from women with systemic lupus erythematosus or antiphospholipid syndrome and recurrent abortions on human placental explants in culture.

Teratology·2002
See all related articles

Area of Science:

  • Pharmacology
  • Teratology
  • Obstetrics

Background:

  • Ergotamine, an ergot alkaloid, is investigated for potential teratogenic effects.
  • Animal studies indicate maternal toxicity is often associated with observed developmental effects.
  • Human clinical reports are anecdotal, with some suggesting malformations consistent with vascular injury.

Purpose of the Study:

  • To evaluate the teratogenic potential of ergotamine.
  • To review existing evidence on ergotamine exposure during pregnancy.
  • To inform clinical recommendations regarding ergotamine use in pregnant women.

Main Methods:

  • Review of animal toxicology data.
  • Analysis of anecdotal human clinical reports.
  • Examination of epidemiologic studies on ergotamine exposure in pregnancy.

Related Experiment Videos

Main Results:

  • Animal studies showed teratogenic effects primarily at maternally toxic doses.
  • Human reports are limited and often anecdotal, with some malformations suggesting vascular injury.
  • Epidemiologic studies have not demonstrated a clear increase in infant malformations with ergotamine exposure.

Conclusions:

  • Ergotamine use in pregnancy carries risks, including potential severe vasospasm affecting both mother and fetus.
  • Ergotamine should be avoided during pregnancy due to potential teratogenic and toxic effects.
  • Counseling for pregnant women with ergotamine exposure should focus on potential toxic risks.